Andras Varro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andras Varro has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Julius Gy Papp
3 shared publicationsJulius Gy. Papp
3 shared publicationsNorbert Iost
3 shared publications- Ladislaus L. Torday
Department of Pharmacology and Pharmacotherapy, Szeged University, Dom ter 12, Szeged 6701, Hungary
2 shared publications Laszlo Virag
2 shared publicationsLászló Virág
11Department of Pharmacology & Pharmacotherapy, Faculty of Medicine, University of Szeged, Szeged, Hungary
2 shared publications
Latest Publications
- 1 October 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 788, 286-293
Block of Na + /Ca 2+ exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation
- 1 October 2016
- Published by Elsevier in European Journal of Pharmacology
- Vol. 788, 286-293
Block of Na + /Ca 2+ exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation
- 1 August 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (20) , 2411-2427
Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Abstract: In this article we overview the most important antiarrhythmic and positive inotropic mechanisms based on pharmacological modification of an ion channel or a transport protein in the surface membrane of cardiac myocytes. First we briefly characterize the ion currents mediated by these proteins in atrial and ventricular cells. Since the level of expression of ion channels is markedly altered in various types of chronic heart diseases, such as atrial fibrillation or heart failure, cardiac remodelling characteristic of these cases is also discussed. The paper gives evaluation of the currently applied most important antiarrhythmic strategies and some insight into the perspectives of the future by reviewing a few but promising mechanisms and drugs that are currently investigated. Positive inotropic agents and mechanisms are similarly treated, focusing primarily on proarrhythmic risks or potential antiarrhythmic effects of these compounds. Based on the backgrounds and aims above, modification of the followings factors is discussed in details: INa, ICa, IKr, IKs, IK1, Ito, IKur, IK,Ach, IK,ATP, If, gap-junction channel, Na+ / K+ pump, Na+ / Ca2+ exchanger, Na+ / H+ exchanger, as well as the intracellular concentrations of sodium and calcium ions. In addition to the critical evaluation of each manipulation, the following general conclusions can be drawn. (1) Since large modifications in action potential parameters are usually disadvantageous at long time scale, combination of the various mechanisms, each represented at a moderate degree, appears to be better. (2) Regarding Class III. antiarrhythmic action, selective potassium channel blockers free of reverse rate-dependent properties should be preferred. (3) Partial inhibition of the Na+ / Ca2+ exchanger may result-paradoxically in an antiarrhythmic action under specific conditions, in addition to its positive inotropic effect. We believe that investigation of new antiarrhythmic mechanisms, rather than new compounds of the old families, might be most beneficial in order to effectively treat life threatening cardiac arrhythmias in the future.
- 1 August 2004
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 10 (20) , 2411-2427
Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Abstract: In this article we overview the most important antiarrhythmic and positive inotropic mechanisms based on pharmacological modification of an ion channel or a transport protein in the surface membrane of cardiac myocytes. First we briefly characterize the ion currents mediated by these proteins in atrial and ventricular cells. Since the level of expression of ion channels is markedly altered in various types of chronic heart diseases, such as atrial fibrillation or heart failure, cardiac remodelling characteristic of these cases is also discussed. The paper gives evaluation of the currently applied most important antiarrhythmic strategies and some insight into the perspectives of the future by reviewing a few but promising mechanisms and drugs that are currently investigated. Positive inotropic agents and mechanisms are similarly treated, focusing primarily on proarrhythmic risks or potential antiarrhythmic effects of these compounds. Based on the backgrounds and aims above, modification of the followings factors is discussed in details: INa, ICa, IKr, IKs, IK1, Ito, IKur, IK,Ach, IK,ATP, If, gap-junction channel, Na+ / K+ pump, Na+ / Ca2+ exchanger, Na+ / H+ exchanger, as well as the intracellular concentrations of sodium and calcium ions. In addition to the critical evaluation of each manipulation, the following general conclusions can be drawn. (1) Since large modifications in action potential parameters are usually disadvantageous at long time scale, combination of the various mechanisms, each represented at a moderate degree, appears to be better. (2) Regarding Class III. antiarrhythmic action, selective potassium channel blockers free of reverse rate-dependent properties should be preferred. (3) Partial inhibition of the Na+ / Ca2+ exchanger may result-paradoxically in an antiarrhythmic action under specific conditions, in addition to its positive inotropic effect. We believe that investigation of new antiarrhythmic mechanisms, rather than new compounds of the old families, might be most beneficial in order to effectively treat life threatening cardiac arrhythmias in the future.
- 1 January 2004
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 11 (1) , 1-11
Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs
One possible mechanism of action of the available K-channel blocking agents used to treat arrhythmias is to selectively inhibit the HERG + MIRP channels, which carry the rapid delayed rectifier outward potassium current (IKr). These antiarrhythmics, like sotalol, dofetilide and ibutilide, have been classified as Class III antiarrhythmics. However, in addition to their beneficial effect, they substantially lengthen ventricular repolarization in a reverse-rate dependent manner. This latter effect, in certain situations, can result in life-threatening polymorphic ventricular tachycardia (torsades de pointes). Selective blockers (chromanol 293B, HMR-1556, L-735,821) of the KvLQT1 + minK channel, which carriy the slow delayed rectifier potassium current (IKs), were also considered to treat arrhythmias, including atrial fibrillation (AF). However, IKs activates slowly and at a more positive voltage than the plateau of the action potential, therefore it remains uncertain how inhibition of this current would result in a therapeutically meaningful repolarization lengthening. The transient outward potassium current (Ito), which flows through the Kv 4.3 and Kv 4.2 channels, is relatively large in the atrial cells, which suggests that inhibition of this current may cause substantial prolongation of repolarization predominantly in the atria. Although it was reported that some antiarrhythmic drugs (quinidine, disopyramide, flecainide, propafenone, tedisamil) inhibit Ito, no specific blockers for Ito are currently available. Similarly, no specific inhibitors for the Kir 2.1, 2.2, 2.3 channels, which carry the inward rectifier potassium current (Ik1), have been developed making difficult to judge the possible beneficial effects of such drugs in both ventricular arrhythmias and AF. Recently, a specific potassium channel (Kv 1.5 channel) has been described in human atrium, which carries the ultrarapid, delayed rectifier potassium current (IKur). The presence of this current has not been observed in the ventricular muscle, which raises the possibility that by specific inhibition of this channel, atrial repolarization can be lengthened without similar effect in the ventricle. Therefore, AF could be terminated and torsades de pointes arrhythmia avoided. Several compounds were reported to inhibit IKur (flecainide, tedisamil, perhexiline, quinidine, ambasilide, AVE 0118), but none of them can be considered as specific for Kv 1.5 channels. Similarly to Kv 1.5 channels, acetylcholine activated potassium channels carry repolarizing current (IKAch) in the atria and not in the ventricle during normal vagal tone and after parasympathetic activation. Specific blockers of IKAch can, therefore, also be a possible candidate to treat AF without imposing proarrhythmic risk on the ventricle. At present several compounds (amiodarone, dronedarone, aprindine, pirmenol, SD 3212) were shown to inhibit IKAch, but none of them proved to be selective. Further research is needed to develop specific K-channel blockers, such as IKur and IKAch inhibitors, and to establish their possible therapeutic value.
- 1 January 2004
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 11 (1) , 1-11
Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs
One possible mechanism of action of the available K-channel blocking agents used to treat arrhythmias is to selectively inhibit the HERG + MIRP channels, which carry the rapid delayed rectifier outward potassium current (IKr). These antiarrhythmics, like sotalol, dofetilide and ibutilide, have been classified as Class III antiarrhythmics. However, in addition to their beneficial effect, they substantially lengthen ventricular repolarization in a reverse-rate dependent manner. This latter effect, in certain situations, can result in life-threatening polymorphic ventricular tachycardia (torsades de pointes). Selective blockers (chromanol 293B, HMR-1556, L-735,821) of the KvLQT1 + minK channel, which carriy the slow delayed rectifier potassium current (IKs), were also considered to treat arrhythmias, including atrial fibrillation (AF). However, IKs activates slowly and at a more positive voltage than the plateau of the action potential, therefore it remains uncertain how inhibition of this current would result in a therapeutically meaningful repolarization lengthening. The transient outward potassium current (Ito), which flows through the Kv 4.3 and Kv 4.2 channels, is relatively large in the atrial cells, which suggests that inhibition of this current may cause substantial prolongation of repolarization predominantly in the atria. Although it was reported that some antiarrhythmic drugs (quinidine, disopyramide, flecainide, propafenone, tedisamil) inhibit Ito, no specific blockers for Ito are currently available. Similarly, no specific inhibitors for the Kir 2.1, 2.2, 2.3 channels, which carry the inward rectifier potassium current (Ik1), have been developed making difficult to judge the possible beneficial effects of such drugs in both ventricular arrhythmias and AF. Recently, a specific potassium channel (Kv 1.5 channel) has been described in human atrium, which carries the ultrarapid, delayed rectifier potassium current (IKur). The presence of this current has not been observed in the ventricular muscle, which raises the possibility that by specific inhibition of this channel, atrial repolarization can be lengthened without similar effect in the ventricle. Therefore, AF could be terminated and torsades de pointes arrhythmia avoided. Several compounds were reported to inhibit IKur (flecainide, tedisamil, perhexiline, quinidine, ambasilide, AVE 0118), but none of them can be considered as specific for Kv 1.5 channels. Similarly to Kv 1.5 channels, acetylcholine activated potassium channels carry repolarizing current (IKAch) in the atria and not in the ventricle during normal vagal tone and after parasympathetic activation. Specific blockers of IKAch can, therefore, also be a possible candidate to treat AF without imposing proarrhythmic risk on the ventricle. At present several compounds (amiodarone, dronedarone, aprindine, pirmenol, SD 3212) were shown to inhibit IKAch, but none of them proved to be selective. Further research is needed to develop specific K-channel blockers, such as IKur and IKAch inhibitors, and to establish their possible therapeutic value.
- 16 October 2002
- Published by Elsevier in Chemical Physics Letters
- Vol. 365 (5-6) , 542-551
Density functional molecular computations on protonated serotonin in the gas phase and various solvent media
- 16 October 2002
- Published by Elsevier in Chemical Physics Letters
- Vol. 365 (5-6) , 542-551
Density functional molecular computations on protonated serotonin in the gas phase and various solvent media
- 1 October 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (3) , 361-368
Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve
The aim of this study was to investigate the possible role of the interaction of different potassium channels in dog ventricular muscle, by applying the conventional microelectrode and whole cell patch‐clamp techniques at 37°C. Complete block of IKr by 1 μM dofetilide lengthened action potential duration (APD) by 45.6±3.6% at 0.2 Hz (n=13). Chromanol 293B applied alone at 10 μM (a concentration which selectively blocks IKs) did not markedly lengthen APD (IKr block with 1 μM dofetilide, inhibition of IKs with 10 μM chromanol 293B substantially delayed repolarization by 38.5±8.2% at 0.2 Hz (n=6). BaCl2, at a concentration of 10 μM which blocks IKl without affecting other currents, lengthened APD by 33.0±3.1% (n=11), but when IKr was blocked with 1 μM dofetilide, 10 μM BaCl2 produced a more excessive rate dependent lengthening in APD, frequently (in three out of seven preparations) initiating early afterdepolarizations. These findings indicate that if only one type of potassium channels is inhibited in dog ventricular muscle, excessive APD lengthening is not likely to occur. Dog ventricular myocytes seem to repolarize with a strong safety margin (‘repolarization reserve’). However, when this normal ‘repolarization reserve’ is attenuated, otherwise minimal or moderate potassium current inhibition can result in excessive and potentially proarrhythmic prolongation of the ventricular APD. Therefore, application of drugs which are able to block more than one type of potassium channel is probably more hazardous than the use of a specific inhibitor of one given sort of potassium channel, and when simultaneous blockade of several kinds of potassium channel may be presumed, a detailed study is needed to define the determinants of ‘repolarization reserve’. British Journal of Pharmacology (2002) 137, 361–368. doi:10.1038/sj.bjp.0704881
- 1 October 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (3) , 361-368
Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve
The aim of this study was to investigate the possible role of the interaction of different potassium channels in dog ventricular muscle, by applying the conventional microelectrode and whole cell patch‐clamp techniques at 37°C. Complete block of IKr by 1 μM dofetilide lengthened action potential duration (APD) by 45.6±3.6% at 0.2 Hz (n=13). Chromanol 293B applied alone at 10 μM (a concentration which selectively blocks IKs) did not markedly lengthen APD (IKr block with 1 μM dofetilide, inhibition of IKs with 10 μM chromanol 293B substantially delayed repolarization by 38.5±8.2% at 0.2 Hz (n=6). BaCl2, at a concentration of 10 μM which blocks IKl without affecting other currents, lengthened APD by 33.0±3.1% (n=11), but when IKr was blocked with 1 μM dofetilide, 10 μM BaCl2 produced a more excessive rate dependent lengthening in APD, frequently (in three out of seven preparations) initiating early afterdepolarizations. These findings indicate that if only one type of potassium channels is inhibited in dog ventricular muscle, excessive APD lengthening is not likely to occur. Dog ventricular myocytes seem to repolarize with a strong safety margin (‘repolarization reserve’). However, when this normal ‘repolarization reserve’ is attenuated, otherwise minimal or moderate potassium current inhibition can result in excessive and potentially proarrhythmic prolongation of the ventricular APD. Therefore, application of drugs which are able to block more than one type of potassium channel is probably more hazardous than the use of a specific inhibitor of one given sort of potassium channel, and when simultaneous blockade of several kinds of potassium channel may be presumed, a detailed study is needed to define the determinants of ‘repolarization reserve’. British Journal of Pharmacology (2002) 137, 361–368. doi:10.1038/sj.bjp.0704881
- 29 January 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (1) , 101-110
Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration
The effects of IKs block by chromanol 293B and L‐735,821 on rabbit QT‐interval, action potential duration (APD), and membrane current were compared to those of E‐4031, a recognized IKr blocker. Measurements were made in rabbit Langendorff‐perfused whole hearts, isolated papillary muscle, and single isolated ventricular myocytes. Neither chromanol 293B (10 μM) nor L‐735,821 (100 nM) had a significant effect on QTc interval in Langendorff‐perfused hearts. E‐4031 (100 nM), on the other hand, significantly increased QTc interval (35.6±3.9%, n=8, PIKs and IKr, respectively. IKs tail currents activated slowly (at +30 mV, τ=888.1±48.2 ms, n=21) and deactivated rapidly (at −40 mV, τ=157.1±4.7 ms, n=22), while IKr tail currents activated rapidly (at +30 mV, τ=35.5±3.1 ms, n=26) and deactivated slowly (at −40 mV, τ1=641.5±29.0 ms, τ2=6531±343, n=35). IKr was estimated to contribute substantially more to total current density during normal ventricular muscle action potentials (i.e., after a 150 ms square pulse to +30 mV) than does IKs. These findings indicate that block of IKs is not likely to provide antiarrhythmic benefit by lengthening normal ventricular muscle QTc, APD, and refractoriness over a wide range of frequencies. British Journal of Pharmacology (2001) 132, 101–110; doi:10.1038/sj.bjp.0703777
- 29 January 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (1) , 101-110
Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration
The effects of IKs block by chromanol 293B and L‐735,821 on rabbit QT‐interval, action potential duration (APD), and membrane current were compared to those of E‐4031, a recognized IKr blocker. Measurements were made in rabbit Langendorff‐perfused whole hearts, isolated papillary muscle, and single isolated ventricular myocytes. Neither chromanol 293B (10 μM) nor L‐735,821 (100 nM) had a significant effect on QTc interval in Langendorff‐perfused hearts. E‐4031 (100 nM), on the other hand, significantly increased QTc interval (35.6±3.9%, n=8, PIKs and IKr, respectively. IKs tail currents activated slowly (at +30 mV, τ=888.1±48.2 ms, n=21) and deactivated rapidly (at −40 mV, τ=157.1±4.7 ms, n=22), while IKr tail currents activated rapidly (at +30 mV, τ=35.5±3.1 ms, n=26) and deactivated slowly (at −40 mV, τ1=641.5±29.0 ms, τ2=6531±343, n=35). IKr was estimated to contribute substantially more to total current density during normal ventricular muscle action potentials (i.e., after a 150 ms square pulse to +30 mV) than does IKs. These findings indicate that block of IKs is not likely to provide antiarrhythmic benefit by lengthening normal ventricular muscle QTc, APD, and refractoriness over a wide range of frequencies. British Journal of Pharmacology (2001) 132, 101–110; doi:10.1038/sj.bjp.0703777